Formulary
Ertugliflozin: Indications, Dosing, Side Effects and Interactions
Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary...
MedNext Academy | 3 min read
Ertugliflozin: Indications, Dosing, Side Effects and Interactions
Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary...
Drug action
Reversibly inhibits sodium-glucose co-transporter 2 (SGLT2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.
Indications and dose
**Type 2 diabetes mellitus as monotherapy (if metformin inappropriate),Type 2 diabetes mellitus in combination with insulin or other antidiabetic drugs (if existing treatment fails to achieve adequate glycaemic control)**
- **Adult** (By Mouth): 5 mg once daily; increased to 15 mg once daily if necessary and if tolerated, dose to be taken in the morning.
Cautions
Dehydration; elderly (risk of volume depletion); history of hypotension Cautions, further information Volume depletion Manufacturer advises correct hypovolaemia before starting treatment-consider interrupting treatment if volume depletion occurs.
Contraindications
Diabetic ketoacidosis; type 1 diabetes mellitus (increased risk of diabetic ketoacidosis)
Side effects
Common or very common Hypoglycaemia; hypovolaemia; increased risk of infection; polydipsia; thirst; urinary disorders; vulvovaginal pruritus Rare or very rare Diabetic ketoacidosis (discontinue immediately) Frequency not known Fournier's gangrene (discontinue and initiate treatment promptly); lower limb amputations; phimosis Side-effects, further information Consider interrupting treatment if volume depletion occurs.
Pregnancy
Manufacturer advises avoid-toxicity in animal studies.
Breast feeding
Manufacturer advises avoid-present in milk in animal studies.
Hepatic impairment
Manufacturer advises avoid in severe impairment (no information available).
Renal impairment
Avoid initiation if eGFR less than 60 mL/minute/1.73 m 2 . M Frequent monitoring of renal function required if eGFR less than 60 mL/minute/1.73 m 2 . M Avoid if eGFR is persistently less than 45 mL/minute/1.73 m 2 . M See Prescribing in renal impairment .
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Ertugliflozin in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

